SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 15.85 |
| Enterprise Value ($M) | 16.21 |
| Book Value ($M) | 1.79 |
| Book Value / Share | 0.01 |
| Price / Book | 8.83 |
| NCAV ($M) | 0.11 |
| NCAV / Share | 0.00 |
| Price / NCAV | 142.76 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.88 |
| Return on Assets (ROA) | -0.28 |
| Return on Equity (ROE) | -1.01 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.22 |
| Current Ratio | 1.02 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 6.24 |
| Assets | 7.93 |
| Liabilities | 6.13 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 15.71 |
| Operating Income | -2.19 |
| Net Income | -2.39 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -0.86 |
| Cash from Investing | -0.03 |
| Cash from Financing | 0.03 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Similar Companies | |
|---|---|
| CSBTF – Kuros Biosciences AG | CUBT – Curative Biotechnology, Inc. |
| CURLF – Curaleaf Holdings, Inc. | CYAN – Cyanotech Corporation |
| CYDY – CytoDyn Inc. |